Overview

Aim to Reduce Movements in Tardive Dyskinesia

Status:
Completed

Trial end date:
2015-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Auspex Pharmaceuticals, Inc.